Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)
admin 7th July 2017 Uncategorised 0Teva Pharmaceutical Industries
More: Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)
Source: MDlinx